Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status

NCT07894458 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07894458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
August 12, 2026
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, lung neoplasms, minimal residual disease, neoadjuvant therapy

Arms

As registered; 1 arm.

  • MRD-Guided Adaptive Postoperative Management Group ExperimentalAdaptive therapy of de-escalation and escalation based on MRD testing and pathological response

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Two-year recurrence-free survival rate Time from curative surgery to confirmation of clinical progression (recurrence or metastasis) within two years.

Lead sponsor's other trials

Peking University People's Hospital, most recent start first.

Similar trials

Same condition (Neoplasm, Residual) and phase, most recent start first.